Skip to main content
main-content

31-07-2017 | Rheumatology | News | Article

News in brief

Markers of collagen degradation decrease with weight loss among patients with OA

medwireNews: Overweight and obese patients with osteoarthritis (OA) who lose weight through lifestyle intervention experience a decrease in levels of collagen degradation markers, suggests a secondary analysis of the IDEA trial.

Such biomarkers could be developed and used “to monitor the effects of an intervention on the joint tissues affected by OA,” say Richard Loeser (University of North Carolina, Chapel Hill, USA) and co-researchers.

The team found that the 144 trial participants randomly assigned to a weight-loss diet and the 140 receiving a diet- and exercise-based intervention had significantly lower levels of C1M – a tissue marker of matrix metalloproteinase-mediated degradation of type 1 collagen – at 6 and 18 months compared with the 145 patients receiving a control exercise only intervention.

Patients in the diet plus exercise group also had significantly lower levels of the marker of type 3 collagen degradation, C3M, at the 6- and 18-month follow-up.

These changes in C1M and C3M, in addition to a decrease in the levels of CRPM – a systemic marker of C-reactive protein degradation – were associated with weight loss among participants in all three groups, and interleukin-6 levels were correlated with changes in C1M, C3M, and CRPM, report the researchers in Osteoarthritis and Cartilage.

And they conclude that “overweight and obese adults with knee OA who lose weight experience reduced inflammation at a systemic as well as tissue level.”

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group​​​​​​​